Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
about
Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymesApplication of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interactionTherapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolitesEffect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers.Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressantInformatics confronts drug-drug interactionsCooperative properties of cytochromes P450.Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database.Application of mechanism-based CYP inhibition for predicting drug-drug interactions.Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.Methodologies used to identify and characterize interactions among antiepileptic drugs.Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics.Advances in predicting CYP-mediated drug interactions in the drug discovery setting.Noncompetitive inhibition of human CYP2C9 in vitro by a commercial Rhodiola rosea product.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.Analysis and prediction of drug-drug interaction by minimum redundancy maximum relevance and incremental feature selection.Mechanisms and Consequences of Drug-Drug Interactions.Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection.Structure-based prediction of the nonspecific binding of drugs to hepatic microsomes.Risk assessment of drug-drug interactions using hepatocytes suspended in serum during the drug discovery process.Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.Drug Distribution. Part 1. Models to Predict Membrane Partitioning.Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies.Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug-drug interactions in rat liver.Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities.
P2860
Q28473113-BC9EB411-58A4-4C6F-A146-C7FF6B50CFAFQ31146882-D9DB7624-3EA1-44F4-BE3A-7C8BA37AADD7Q34345596-D26252CF-4BEA-40C0-8F3C-1AF3254A23B2Q34476096-FFE77787-81EB-428A-B8ED-683EAE5F5996Q36105348-DBDD5CB7-FEF6-450F-A644-0E3C8AB8DFE3Q36729945-00C768FE-E9DB-46B9-8366-CFCF3C099924Q37177088-C3D97EA7-CF1A-4C74-949F-0918BAB3374AQ37257012-687EC118-5694-4DEC-9F46-4F72D5E34567Q37366156-1FC40F43-C51B-44A3-B816-19AC003816DDQ37392766-EE174DC8-0730-4A6F-A37C-267FFB7876F0Q37494640-DE7418E9-9680-404C-B4F8-B6F4661725DFQ37965706-AEEF0AD2-32E4-4A03-B311-416C65EFB556Q38018676-90783B65-2A5A-4724-9B20-1FBAA14EC699Q38083753-2AAD58C4-5A39-4E35-8045-82957D5876D5Q38089823-2EBD1C18-F7F7-4E52-924D-D4B55F74B841Q38625997-56F1E00B-43D7-44E2-8439-58236D6DCD41Q38800092-26A4CDA7-2EC9-4BC8-A39A-242D37611033Q40124339-738B0432-4E4C-4738-9EA2-BE7C517834CFQ40306549-0CA64180-CA7A-4364-B6AF-698D333AD03BQ41812027-C5DF17AF-D299-481B-88D2-760B2A51F745Q43117322-16A482BA-E14A-4FE9-AD5F-1E955A8A64F6Q44795024-66B10C9D-9D4A-41E3-9E9D-E835F5C2548FQ46107342-5B083A89-1C64-494B-ACC1-6B66B45DF69FQ46445351-10A4A130-22F5-419B-AAAC-02357AA34D51Q47420860-F6E8478F-22E2-4A2F-9C86-97EE2A6C4325Q51630491-3A6433B5-AEFE-46D7-9F7A-6C4AD52E1424Q52334679-23E8B9E4-FA87-4E9E-A230-84E05DF3EC65Q53203053-6AD0EE7A-AD24-491D-B629-8456F91117FD
P2860
Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Prediction of in vivo drug-dru ...... ing CYP2C9, CYP2D6 and CYP3A4.
@ast
Prediction of in vivo drug-dru ...... ing CYP2C9, CYP2D6 and CYP3A4.
@en
type
label
Prediction of in vivo drug-dru ...... ing CYP2C9, CYP2D6 and CYP3A4.
@ast
Prediction of in vivo drug-dru ...... ing CYP2C9, CYP2D6 and CYP3A4.
@en
prefLabel
Prediction of in vivo drug-dru ...... ing CYP2C9, CYP2D6 and CYP3A4.
@ast
Prediction of in vivo drug-dru ...... ing CYP2C9, CYP2D6 and CYP3A4.
@en
P1476
Prediction of in vivo drug-dru ...... ing CYP2C9, CYP2D6 and CYP3A4.
@en
P2093
Hayley S Brown
J Brian Houston
P304
P356
10.2165/00003088-200645100-00006
P577
2006-01-01T00:00:00Z
P6179
1017799013